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Abstract: Factors controlling complement activation appear to exert a protective effect on pregnancy. This is
particularly important in women with thrombophilia. The aim of this study was to determine the transcript and
protein levels of complement decay-accelerating factor (DAF) and membrane cofactor protein (MCP) in the
placentas of women with acquired and inherited thrombophilia. Also, we assessed immunohistochemistry stain-
ing of inhibitors of the complement cascade, DAF and MCP proteins, in the placentas of thrombophilic women.
Placentas were collected from eight women with inherited thrombophilia and ten with acquired thrombophilia.
The levels of DAF and MCP transcripts were evaluated by qPCR, the protein level was evaluated by Western
blot. We observed a higher transcript (p < 0.05) and protein (p < 0.001) levels of DAF and MCP in the placentas
of thrombophilic women than in the control group. DAF and MCP were localized on villous syncytiotrophoblast
membranes, but the assessment of staining in all groups did not differ. The observed higher expression level of
proteins that control activation of complement control proteins is only seemingly contradictory to the changes
observed for example in the antiphospholipid syndrome. However, given the hitherto known biochemical changes
associated with thrombophilia, a mechanism in which increased expression of DAF and MCP in the placentas is
an effect of proinflammatory cytokines, which accompanies thrombophilia, is probable. (Folia Histochemica et
Cytobiologica 2012, Vol. 50, No. 3, 460–467)
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Introduction
Antiphospholipid Syndrome (APS) and coexisting
thrombosis are being extensively studied as potential
causes of pregnancy loss. The loss is more likely to
occur in the first trimester of pregnancy as a result of
impaired implantation, whereas intrauterine demise,
placental abruption or preeclampsia are more fre-
quent in later pregnancy [1]. Although the frequency
of thrombophilia in pregnant women is lower than
previously believed, the association between various
types of antiphospholipid (aPL) antibodies, factor V
Leiden and prothrombin mutation is an evident cause
of pregnancy complications [2].
Despite numerous studies, the mechanism of
pregnancy loss in women with APS remains unclear.
Antiphospholipid antibodies (aPL) in vitro inhibit
the anticoagulant function of annexin V, protein C
and block fibrinolysis [3–6]. Besides activating the
complement cascades, aPL (including b2-glycopro-
tein1 antibodies (anti-b2GP1) in the placenta) blocks
the b2GP1 protein as a ligand for receptors on epi-
thelial and trophoblast cells surface, resulting in
decreased hCG production and impaired expression
of protein on cell surface (integrins, catherins).
Anti-b2GP1 binding to trophoblast blocks its invasion
inducing apoptosis. Anti-b2GP1 has been observed to
affect trophoblast function, decreasing the expression
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of the growth factor: heparin binding EGF-like fac-
tor (HB-EGF) [7].
Complement activation due to aPL induces inflam-
matory reaction through proinflammatory cytokines
including TNFa, thus impairing the balance between
Th1/Th2 which is favorable in pregnancy [8]. The
inflammatory reaction is also present in thrombophil-
ia not related to APS. The key moment of this process
is the activation of prothrombin into thrombin. Throm-
bin has a wide spectrum of action, fusing together proin-
flammatory and prothrombotic action and stimulating
proinflammatory cytokine expression [9, 10].
Tissues including placenta possess the ability to inhibit
complement cascade through the presentation of recep-
tors for complement elements and membrane proteins
degrading complement elements on the surface of cells.
The complement decay-accelerating factor (DAF), also
known as CD55, is among many well-studied complement
control proteins. This membrane protein prevents the as-
sembly of the C3bBb complex, thus blocking the forma-
tion of the membrane attack. Another well-known com-
plement inhibitory factor is the membrane cofactor pro-
tein (MCP), also known as CD46. MCP protects the host
cells from damage as cofactor for inactivation of comple-
ment components C3b and C4b by serum factor I.
It has been demonstrated that murine homozy-
gotes without the Crry (Crry-/-) gene, encoding pro-
tein of analog action to human DAF and MCP, expe-
rience fetal absorption or growth impairment [11, 12].
The role of the complement controlling cascade fac-
tors in thrombophilia is poorly understood. Rai et al.
(in 2006) showed that in non-conception cycle, the level
of mRNA for DAF in the endometrium of APS patients
is statistically lower compared to healthy women [13].
We can speculate that activation of complement cas-
cade in APS may be associated with weakened expres-
sion of complement cascade inhibitors. Secondary com-
plement activation takes place also in inherited throm-
bophilia through thrombin activation [10]. To date there
have been very few papers concerning molecular changes
in the placentas of women with thrombophilia. Nor is
the status of complement controlling factors in throm-
bophilic patients well understood.
The aim of this study was to investigate whether
in the placentas of thrombophilic women there is an
altered expression of DAF and MCP proteins, and
whether differences in the expression of these pro-
teins are dependent on the form of thrombophilia.
Material and methods
Material. The study was conducted at the Division of Re-
production, Department of Obstetrics and Gynecology,
Karol Marcinkowski Poznan University of Medical Scienc-
es, Poland, in 2011.
We analyzed 19 placentas from 18 patients with inherited
(n = 8) and acquired (n = 10) thrombophilia; 20 placentas
from uneventful pregnancies which resulted in the delivery
of a healthy infant constituted the control group (n = 20).
Patients with APS fulfilled at least one clinical and one
laboratory criterion. Clinical criteria included: (1) three or
more early miscarriages; or (2) two consecutive late miscar-
riages (beyond 12 weeks of gestation); or (3) intrauterine
fetal death beyond ten weeks of gestation of unknown cause
or delivery before 34 gestational weeks complicated by
preeclampsia with placental insufficiency; or (4) thrombot-
ic episodes.
Laboratory criteria included: (1) presence of lupus an-
ticoagulant (LA); (2) moderate to high titers (≥ 20 GPL or
MPL) of anticardiolipin antibodies (aCL) or substantial ti-
ters (> 99 percentile) of anti-b2GP1. In molecular tests, eight
women were diagnosed with inherited thrombophilia: fac-
tor V Leiden was found in five, hyperhomocysteinemia in
two, and protein S deficiency in one patient. All pregnant
patients diagnosed with thrombophilia were treated with
either prophylactic or therapeutic doses of LMWH and/or
aspirin, depending on their weight and thrombotic episodes.
The clinical characteristics of the studied groups are shown
in Table 1.
The study protocol was approved by the local ethical
committee and the patients signed an informed consent
form. All coagulation tests were performed at the Hemo-
stasis Laboratory of Medical University Hematology De-
partment in Poznan. The laboratory has a TUV Rheinland
ISO9001 certificate.
Method. Directly after birth, a small part of the placenta
was placed in RNAlater and frozen at minus 20°C, for the
assessment of transcript levels. Another part was frozen in
liquid nitrogen (LN) until Western blot assessment was per-
formed. The specimens included both maternal and fetal
fragments, but the decidual and amniochorional membranes
were removed. The entire placenta was fixed in buffered
formalin for histopathological assessment and DAF and
MCP immunolocalization.
RNA isolation and Real-time quantitative PCR (RQ-PCR)
analysis of DAF and MCP transcript levels. Total RNA was
isolated from 30 mg of placenta by RNeasy Protect Mini
Kit Qiagen (Hilden, Germany). RNA samples were treated
with DNase I from DNase Set Qiagen (Hilden, Germany),
quantified, and 1 μg reverse-transcribed into cDNA, using
QuantiTect Reverse Transcription Kit and random hexam-
er primers from Qiagen (Hilden, Germany). RQ-PCR was
conducted in a Corbett Research Rotor-Gene 3000 ther-
mocycler (Mortlake, Australia). Target cDNA was quanti-
fied using the relative quantification method employing
a calibrator. The calibrator was prepared as a cDNA mix from
all patients and control samples and consecutive dilutions
were used to create a standard curve as provided in the
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Table 1. Clinical characteristics of women with thrombophilia and control group
Characteristics Inherited thrombophilia Acquired thrombophilia Control group
(n = 8) (n = 10) (n = 20)
Maternal characteristics
Maternal age (mean ± SD) 30.2 ± 3.16 31.4 ± 3.04 29.7 ± 3.97
Gravity (mean ± SD) 1.75 ± 1.39 2.18 ± 1.6 1.1 ± 0.31
Parity (mean ± SD) 0.38 ± 0.52 0.55 ± 0.93 1.1 ± 0.31
History of pregnancy failures* –
Early miscarriages 2 4 –
Late miscarriages 2 2 –
IUD 3 4 –
Previous thrombotic episodes 2 5 –
Laboratory criteria** –
aCL – 6
anti-b2GPI – 1
LA – 7
F V Leiden 5 –
Hyperhomocysteinemia 2 –
Protein S deficiency 1 –
Characteristics of current pregnancy
Placental weight [g] 562.86 ± 164.39 509.55 ± 226.54 530.0 ± 96.57
Fetal weight [g] 2,893.75 ± 1,285.22 2,578.33 ± 1,269.47 3,351.0 ± 398.15
Gestation age (wk) 36.75 ± 3.99 34.91 ± 6.35 39.2 ± 1.32
Vaginal delivery 3 5 15
Cesarean section 5 5 5
*A number of women with thrombophilia showed more than one clinical criterion eligible for laboratory diagnostics;
**In two patients with acquired thrombophilia, we found concurrence of aCL and LA; in one concurrence of aCL, LA, and anti-b2GPI
Relative Quantification Manual from Roche Diagnostics
GmbH (Mannheim, Germany).
For amplification, 60 ng of total cDNA solution was add-
ed to 20 μl (total) of DyNAmo HS SYBR® Green qPCR
Kit from Finnzymes (Espoo, Finland) and primers (Table 2).
One RNA sample of each preparation was processed with-
out the reverse transcription (RT)-reaction to provide
a negative control in subsequent PCR. The quantity of in-
vestigated transcripts in each sample was standardized by
human b-actin (ACTB) transcript levels. The DAF and MCP
mRNA levels were expressed as the multiplicity of these
cDNA concentrations in the calibrator.
Protein isolation and Western blot analysis. The crushed
in LN material was mixed with SB buffer (125 mM Tris-
HCl pH 6.8, 4% SDS, 20% glycerol, 10% 2-mercaptoetha-
Table 2. Sequence of primers used for qPCR
Gene Sequence (5’-3’ direction)* Position ENST number Product
www. ensembl.org size (bp)
DAF GGTGCAACCATCTCCTTCTC +805; +825
00000196352 141TGG TGG TGC TGG ACA ATA AA +926; +946
MCP TTGATTGTACCAAGGGATGGA +2,537; +2,558
AACTGCTTGGCTAAGGGACTC +2,615; +2,636 00000117335 99
ACTB GCACCACACCTTCTACAATGAGC +450; +473
GGATAGCACAGCCTGGATAGCAAC +592; +616 00000331789 166
*Source: http://medgen.ugent.be/rtprimerdb/ last accessed: 19 Aug. 2011
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nol) and total protein concentration was estimated using
a commercial 2-D Quant kit (GE Healthcare). Samples con-
taining 30 μg of protein were separated by electrophoresis
in a 4–12% SDS-polyacrylamide gel (Bis-Tris NuPAGE, In-
vitrogen). The separated proteins were transferred to
a PVDF membrane and blocked with TBST (TBS plus 0.1%
Tween-20) containing 4% BSA.
Immunodetection was processed with the use of rab-
bit polyclonal antibody anti-DAF (H-319, 200 μg/ml) and
rabbit polyclonal antibody anti-MCP (H-294; 200 μg/ml)
in 1:200 concentrations (SantaCruz, USA). For ACTB de-
tection, rabbit polyclonal anti-ACTB antibody was used
in a 1:400 concentration (N-21; 100 μg/ml), (SantaCruz,
USA). Goat anti-rabbit, conjugated with Alexa Fluor 663
(Invitrogen, USA), was used as the secondary antibody.
Bands were revealed using the Fuji FLA5100 (FujiFilm,
Japan) scanner. The quantities of Western blot-detected
DAF, MCP and b-actin proteins were determined based on
the band optical density. The band densitometry readings
were normalized to ACTB loading control to calculate the
studied protein to b-actin optical density ratio. As refer-
ence for statistical calculations, the mean value of DAF and
MCP in the control group was determined as 1.00.
Immunohistochemistry. Samples from the placenta in un-
changed regions were taken for immunohistochemistry.
Specimens were preserved in buffered formalin (pH 7.4–
–7.6), immersed in paraffin blocks and dissected into pieces
up to 3–4 μm thick. A part of the sections was stained with
hematoxylin and eosin (H + E) and neighboring sections
underwent immunohistochemical staining to identify the
presence of DAF and MCP antigen. Retrieval of antigens
was processed in Retrieval Solution Buffer (DAKO, Den-
mark), 98.5°C. To detect DAF and MCP, the same primary
antibodies were used as in WB analysis in 1:100 dilution.
Reaction with secondary antibodies and staining were per-
formed with Dako REAL™EnVision™ Detection System
Peroxidase/DAB, (DAKO, Denmark). With every series of
staining, we performed a negative control without primary
antibody.
Assessment of the immunohistochemical reaction was
conducted by a pathologist in random order, with no knowl-
edge of the study group affinity. The expression of DAF
and MCP proteins was assessed with the use of a 0–3 point
scale (0 — no reaction (Figure 1A); 1 — weak reaction,
discontinuous in both membranes in over 50% of the villi
(Figure 1B); 2 — distinct reaction, continuous in one of the
Figure 1. Immunohistochemical staining for DAF and MCP proteins, magnification × 400. Lack of reaction (A). Subtle
reaction in the outer membrane of syncytiotrophoblast (arrow) (B). Continuous reaction in the outer membrane of
syncytiotrophoblast (arrow); discontinuous in the basement membrane (dual arrow) (C). Continuous reaction in both
membranes of syncytiotrophoblast: superficial (arrow) and basal (dual arrow) (D)
A
B
C
D
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membranes in more than 50% of the villi (Figure 1C); 3 —
distinct reaction in both membranes in more than 50% of
the villi (Figure 1D).
Statistical analysis. For statistical analysis, SigmaStat3.5
software was used. The analysis of the results was based on
the Mann–Whitney Rank Sum test and Chi Square test for
staining assessment. p < 0.05 was considered statistically
significant.
Results
Levels of DAF and MCP transcript and protein in
placentas of women with thrombophilia and controls
We used RQ-PCR and Western blot analysis to
evaluate DAF and MCP transcript and protein lev-
els, respectively, in the placentas of women diag-
nosed with thrombophilia and the controls. In wom-
en with acquired thrombophilia, we observed signif-
icantly higher levels (p < 0.05) of DAF and MCP
transcript in placentas with APS group compared to
controls: 2.2 times for DAF and 2.29 times for MCP.
In placentas from women with inherited thrombo-
philia, we also observed significantly higher levels
(p < 0.05) of DAF and MCP transcript in placentas
from the thrombosis group compared to controls:
4.52 times for DAF and 3.74 times for MCP (Table 3,
Figures 2A, B).
We also found significantly higher levels of DAF
and MCP protein (p < 0.001) in placentas with ac-
quired thrombophilia compared to controls: 3.26
times for DAF and 3.83 times for MCP. In the in-
herited thrombophilia group, we found 3.08 times
higher level of DAF protein and 3.94 times higher
level of MCP protein (p < 0.001) (Table 3, Figures
3A, B). Additionally, we found no difference in tran-
scripts and proteins DAF and MCP between the in-
herited and acquired thrombophilia groups (data not
shown).
Immunohistochemistry staining
Generally, a strong color reaction in the chorion syn-
cytiotrophoblast membranes was observed for both
tested proteins. Statistical analysis showed no statis-
tically significant differences in the scale of staining
for MCP and DAF. The results of histological evalu-
ation of microscope slides, stained for the presence
of proteins DAF and MCP, are shown in Table 4. In
samples of the controls, stained with the anti-DAF
antibody, a higher (although not statistically signifi-
cant) percentage of staining assessed as 3 points, and
a higher percentage of staining evaluated at 0 and 1
in the group of placentas from thrombophilic wom-
en, is worth noting. Ta
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Discussion
Expression of complement activation proteins in-
cluding MCP and DAF in trophoblast tissue is al-
ready observed in the first trimester of pregnancy.
A strong expression of these proteins on trophoblast
surface activates the mechanisms protecting the fe-
Figure 2. Relative transcript level of DAF (A) and MCP (B) in placentas from women with acquired and inherited
thrombophilia and control group. To normalize the quantity of transcripts in each sample, DAF and MCP mRNA levels
were normalized to the amount of ACTB cDNA. The boxes and the middle lines correspond to the values from the lower
to upper quartiles and medians, respectively. *p < 0.05
Figure 3. Protein levels for DAF (A) and MCP (B) and representative picture of Western blot analysis (below plots). The
amount of Western blot-detected proteins was presented as the DAF/MCP-to-b-actin band optical density ratio. The boxes
and the middle lines correspond to the values from the lower to upper quartiles and medians, respectively. *p < 0.001
tus from maternal immunological response [14,
15]. Hill et al. (1995) did not find any differences
in DAF and MCP expression in the placentas of
women with recurrent pregnancy losses in the first
trimester compared to healthy fertile women [16].
Rai et al. (2006) proved a decreased transcript
level of DAF in the endometrium of women with
Table 4. Assessment of immunohistochemical staining for DAF and MCP proteins. The table shows the number of
patients presenting successive staining steps (0–3) of tissues for the presence of DAF and MCP
Degree of immunohisto-
chemical assessment DAF
a MCPb
0 1 2 3 0 1 2 3
Acquired thrombophilia (%) 0 2 (18%) 9 (82%) 0 0 0 4 (36%) 7 (64%)
Inherited thrombophilia (%) 1 (12.5%) 3 (37.5%) 3 (37.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 3 (37.5%) 3 (37.5%)
Control group (%) 0 1 (5%) 13 (65%) 6 (30%) 0 0 7 (35%) 13 (65%)
aChi2, p = 0.099; bChi2, p = 0.201
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APS [13]. There is no data regarding the expres-
sion of complement activating proteins in mature
placentas of thrombophilic women. Our results are
in contrast with common scheme, where insuffi-
cient placental protection from DAF favors C3
convertase activation, resulting in inflammatory
reaction in the placenta.
We observed significantly increased mRNA and
protein expression of DAF and MCP in the pla-
centas of women either with inherited thrombo-
philia or related to APS. It seems less likely that
high expression of factors controlling the initial
stage of complement cascade in APS women is
primary. Otherwise we would have never observed
the aPL related proinflammatory effect. aPL in-
hibiting the expression of HB-EGF would give an
opposite effect to the one we found. The relation-
ship between HB-EGF expression and DAF and
MCP [17, 18] has been proved in both in vitro and
in vivo studies.
An inhibiting function of aPL on HB-EGF secre-
tion was confirmed in vitro only for the anti-b2GP1
antibody. Simultaneously, it was confirmed that
LMWH inhibits reaction of anti- b2GP1 with tropho-
blast [10].The influence of other types of antibodies
on HB-EGF expression has not been determined.
In our study, in the group of women with APS,
only one woman had an elevated titer of anti-b2GP1.
We cannot exclude the possibility that the high ex-
pression of DAF and MCP in women with APS is in-
directly a result of the treatment with therapeutic
doses of LMWH or aspirin. In our study we found
a statistically higher expression of DAF and MCP in
both variants of thrombophilia.
There is no convincing data that could explain
a primary high level of DAF and MCP in the placen-
tas of women with inherited thrombophilia, where the
inflammatory reaction mediator is likely the throm-
bin [10, 19]. LMWH mechanism of action known from
APS related thrombophilia is not applicable there.
Considering the lack of difference in DAF and MCP
level in both types of thrombophilia, it is less likely
that LMWH has a stimulating effect on HB-EGF
expression and indirectly on DAF and MCP.
Mason et al. (1999) observed a stimulating influ-
ence of TNFa in vitro on DAF expression in endot-
helial cells. There was no analog reaction as far as
MCP was concerned [20]. Increased DAF expression
found in our studies can be explained as a secondary
response of placental tissue to inflammatory reaction
and the presence of proinflammatory cytokine that
can activate complement cascade in a secondary way
[9, 10, 20]. Lack of similar observations in MCP in
the referenced literature might be a result of the lim-
ited possibilities of an in vitro model. It is very likely
that a similar mechanism of secondary response to
inflammation is associated with MCP expression in
vivo. We support the theory that the DAF and MCP
expression, as a secondary reaction to proinflamma-
tory factors, is more likely. The presence of proin-
flammatory cytokines and thrombin is common for
both variants of thrombophilia. Further studies are
needed in order to explain this phenomenon.
Considering the limitation of quantitative analy-
sis of protein expression in specimens stained immuno-
histochemically, only qualitative differences in placen-
tal distribution DAF and MCP were analyzed. There
were no statistically significant differences in the evalu-
ation of distribution of both proteins in the placenta,
indicating no differences in cells mechanism responsi-
ble for the expression of analyzed placental factors.
To the best of our knowledge, this is the first pub-
lication analyzing the expression of DAF and MCP
in the placentas of thrombophilic women. In this study
we did not estimate the cytokine level. However, tak-
ing into consideration the abovementioned publica-
tion results of Mason et al., we can expect an elevat-
ed level of proinflammatory cytokines in the placen-
tas of the thrombophilic group. Further studies are
needed to elucidate whether proinflammatory cytok-
ines in the placenta influence the expression of DAF
and MCP expression and, if they do, what spectrum
should be taken into consideration.
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